Erbstatin

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H584388

CAS#: 100827-28-9

Description: Erbstatin is a tyrosine protein kinase inhibitor that when combined with foroxymithine has been shown to have antineoplastic activity against L-1210 leukemia.

Chemical Structure

img
Erbstatin
CAS# 100827-28-9
Instruction

Theoretical Analysis

Hodoodo Cat#: H584388
Name: Erbstatin
CAS#: 100827-28-9
Chemical Formula: C9H9NO3
Exact Mass: 179.06
Molecular Weight: 179.175
Elemental Analysis: C, 60.33; H, 5.06; N, 7.82; O, 26.79

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Erbstatin

IUPAC/Chemical Name: Formamide, N-(2-(2,5-dihydroxyphenyl)ethenyl)-, (E)-

InChi Key: SIHZWGODIRRSRA-ONEGZZNKSA-N

InChi Code: InChI=1S/C9H9NO3/c11-6-10-4-3-7-5-8(12)1-2-9(7)13/h1-6,12-13H,(H,10,11)/b4-3+

SMILES Code: O=CN/C=C/C1=CC(O)=CC=C1O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 179.18 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Imoto M, Umezawa K, Komuro K, Sawa T, Takeuchi T, Umezawa H. Antitumor activity of erbstatin, a tyrosine protein kinase inhibitor. Jpn J Cancer Res. 1987 Apr;78(4):329-32. PubMed PMID: 3108212.

2: Zhang ZH, Rhodes KJ, Childers WE, Argentieri TM, Wang Q. Disinactivation of N-type inactivation of voltage-gated K channels by an erbstatin analogue. J Biol Chem. 2004 Jul 9;279(28):29226-30. Epub 2004 May 10. PubMed PMID: 15136567.

3: McIntyre BS, Sylvester PW. Genistein and erbstatin inhibition of normal mammary epithelial cell proliferation is associated with EGF-receptor down-regulation. Cell Prolif. 1998 Feb;31(1):35-46. PubMed PMID: 9666817.

4: Stanwell C, Ye B, Yuspa SH, Burke TR Jr. Cell protein cross-linking by erbstatin and related compounds. Biochem Pharmacol. 1996 Aug 9;52(3):475-80. PubMed PMID: 8687502.

5: Naccache PH, Gilbert C, Caon AC, Gaudry M, Huang CK, Bonak VA, Umezawa K, McColl SR. Selective inhibition of human neutrophil functional responsiveness by erbstatin, an inhibitor of tyrosine protein kinase. Blood. 1990 Nov 15;76(10):2098-104. PubMed PMID: 2173635.

6: Bishop WR, Petrin J, Wang L, Ramesh U, Doll RJ. Inhibition of protein kinase C by the tyrosine kinase inhibitor erbstatin. Biochem Pharmacol. 1990 Nov 1;40(9):2129-35. PubMed PMID: 2242040.

7: Treuner M, Böhmer FD, Schulze W, Petuchov SP, Grosse R. Limited selectivity of a synthetic erbstatin derivative for tyrosine kinase and cell growth inhibition. Biochem Int. 1992 Mar;26(4):617-25. PubMed PMID: 1319149.

8: Takekura N, Yasui W, Kyo E, Yoshida K, Kameda T, Kitadai Y, Abe K, Umezawa K, Tahara E. Effects of tyrosine kinase inhibitor, erbstatin, on cell growth and growth-factor/receptor gene expression in human gastric carcinoma cells. Int J Cancer. 1991 Apr 1;47(6):938-42. PubMed PMID: 1849125.

9: Sugata D, Yamashita K, Umezawa K. Inhibition of serum-induced M-phase progression by a tyrosine kinase inhibitor, erbstatin. Biochem Biophys Res Commun. 1993 Jul 15;194(1):239-45. PubMed PMID: 8333839.

10: Markovits J, Larsen AK, Ségal-Bendirdjian E, Fossé P, Saucier JM, Gazit A, Levitzki A, Umezawa K, Jacquemin-Sablon A. Inhibition of DNA topoisomerases I and II and induction of apoptosis by erbstatin and tyrphostin derivatives. Biochem Pharmacol. 1994 Aug 3;48(3):549-60. PubMed PMID: 8068042.

11: Kawada M, Tawara J, Tsuji T, Honma Y, Hozumi M, Wang JY, Umezawa K. Inhibition of Abelson oncogene function by erbstatin analogues. Drugs Exp Clin Res. 1993;19(6):235-41. Review. PubMed PMID: 8013266.

12: Imoto M, Umezawa K, Sawa T, Takeuchi T, Umezawa H. In situ inhibition of tyrosine protein kinase by erbstatin. Biochem Int. 1987 Nov;15(5):989-95. PubMed PMID: 3501720.

13: Kryukova Y, Rybin VO, Qu J, Steinberg SF, Robinson RB. Age-dependent differences in the inhibition of HCN2 current in rat ventricular myocytes by the tyrosine kinase inhibitor erbstatin. Pflugers Arch. 2009 Feb;457(4):821-30. doi: 10.1007/s00424-008-0565-7. Epub 2008 Aug 12. PubMed PMID: 18696104; PubMed Central PMCID: PMC2701652.

14: Isshiki K, Imoto M, Sawa T, Umezawa K, Takeuchi T, Umezawa H, Tsuchida T, Yoshioka T, Tatsuta K. Inhibition of tyrosine protein kinase by synthetic erbstatin analogs. J Antibiot (Tokyo). 1987 Aug;40(8):1209-10. PubMed PMID: 3680036.

15: Watanabe Y, Kakeya H, Ikoma E, Umezawa K. Induction of morphological and enzymic differentiation in rat pheochromocytoma PC12h cells by stable erbstatin analogues. Drugs Exp Clin Res. 1993;19(1):1-6. PubMed PMID: 8223134.

16: Isshiki K, Imoto M, Takeuchi T, Umezawa H, Tsuchida T, Yoshioka T, Tatsuta K. Effective synthesis of erbstatin and its analogs. J Antibiot (Tokyo). 1987 Aug;40(8):1207-8. PubMed PMID: 3680035.

17: Salari H, Duronio V, Howard SL, Demos M, Jones K, Reany A, Hudson AT, Pelech SL. Erbstatin blocks platelet activating factor-induced protein-tyrosine phosphorylation, polyphosphoinositide hydrolysis, protein kinase C activation, serotonin secretion and aggregation of rabbit platelets. FEBS Lett. 1990 Apr 9;263(1):104-8. PubMed PMID: 1691984.

18: Toi M, Mukaida H, Wada T, Hirabayashi N, Toge T, Hori T, Umezawa K. Antineoplastic effect of erbstatin on human mammary and esophageal tumors in athymic nude mice. Eur J Cancer. 1990;26(6):722-4. PubMed PMID: 2144161.

19: Simizu S, Imoto M, Masuda N, Takada M, Umezawa K. Involvement of hydrogen peroxide production in erbstatin-induced apoptosis in human small cell lung carcinoma cells. Cancer Res. 1996 Nov 1;56(21):4978-82. PubMed PMID: 8895753.

20: Umezawa H, Imoto M, Sawa T, Isshiki K, Matsuda N, Uchida T, Iinuma H, Hamada M, Takeuchi T. Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3. J Antibiot (Tokyo). 1986 Jan;39(1):170-3. PubMed PMID: 3005217.